New York, New York--(Newsfile Corp. - December 15, 2025) - Kuehn Law, PLLC, a shareholder litigation law firm, is investigating whether certain officers and directors of Skye Bioscience, Inc. (NASDAQ: SKYE) breached their fiduciary duties to shareholders.

According to a federal securities lawsuit, Insiders at Skye Bioscience caused the company to misrepresent or fail to disclose that: (i) nimacimab was less effective than represented; (ii) accordingly, nimacimab's clinical, regulatory, and commercial prospects were overstated; and (iii) as a result, public statements were materially false and misleading at all relevant times.

If you currently own SKYE and purchased prior to November 4, 2024 please contact Justin Kuehn, Esq. by email at justin@kuehn.law or call (833) 672-0814. Kuehn Law pays all case costs and does not charge its investor clients. Shareholders should contact the firm immediately as there may be limited time to enforce your rights.

Why Your Participation Matters:

As a shareholder your voice matters, and by getting involved, you contribute to the integrity and fairness of the financial markets. Your investment. Your voice. Your future.™

For additional information, please visit Shareholder Derivative Litigation - Kuehn Law.

Attorney advertising. Prior results do not guarantee similar outcomes.

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/278072

Source: Kuehn Law, PLLC